| Cash Flow | 2025-09-30 |
|---|---|
| Net loss | -9,906,504 |
| Share-based compensation | 111,277 |
| Depreciation and amortization expense | 165,792 |
| Non-cash rent expense | -27,393 |
| Change in fair value of accompanying warrant liability | 4,390,726 |
| Change in fair value of contingent consideration | -12,763 |
| Effect of foreign currency remeasurement | -32,644 |
| Accounts receivable, non-trade | -10,190 |
| Prepaid insurance expense | -517,874 |
| Accounts payable | 216,359 |
| Accrued expenses and other current liabilities | 718,261 |
| Operating lease liabilities | -31,104 |
| Deferred tax liability | -34,793 |
| Net cash used in operating activities | -3,794,648 |
| Proceeds from the sale of equity, net of issuance costs | 3,253,615 |
| Net cash provided by (used in) financing activities | 3,253,615 |
| Effect of exchange rate on changes on cash, cash equivalents, and restricted cash | -19,455 |
| Net decrease in cash, cash equivalents, and restricted cash | -560,488 |
| Cash and cash equivalents at beginning of period | 14,288,690 |
| Cash and cash equivalents at end of period | 13,728,202 |
Neuphoria Therapeutics Inc. (NEUP)
Neuphoria Therapeutics Inc. (NEUP)